Lutetium-177 PSMA Therapy for Advanced Prostate Cancer: What International Patients Should Know

Unlike conventional systemic treatments that circulate throughout the body without targeting one specific tumor marker, Lutetium-177 PSMA belongs to a class of treatments known as radioligand therapy. It combines a molecule designed to recognize prostate-specific membrane antigen — PSMA — with the radioactive isotope Lutetium-177.

The objective is to deliver radiation preferentially to cancer cells that express PSMA.

For patients exploring advanced prostate-cancer treatment options, however, the central question is not simply whether Lutetium-177 PSMA is available.

The more important question is:

Is this treatment appropriate for this particular patient, at this particular stage of the disease?

What is PSMA?

PSMA — prostate-specific membrane antigen — is a protein expressed on the surface of many prostate cancer cells.

In advanced prostate cancer, PSMA can be highly expressed in tumor tissue and metastatic lesions.

This makes PSMA useful in two related ways:

• diagnostically, by helping physicians locate PSMA-expressing disease using molecular imaging;
• therapeutically, by allowing a PSMA-targeting molecule to carry radioactive material toward those cancer cells.

This combination of diagnosis and treatment is often described as theranostics.

Why is PSMA PET important?

Before PSMA-targeted treatment is considered, physicians generally need to establish that the patient's cancer expresses sufficient PSMA.

This is done using an approved PSMA PET scan.

The scan can help identify:

• where PSMA-positive disease is located;
• how extensive the disease is;
• whether relevant tumor sites demonstrate sufficient uptake;
• and whether significant disease exists that may not be adequately PSMA-positive.

This step matters because Lutetium-177 PSMA therapy depends on having the correct biological target.

A diagnosis of metastatic prostate cancer alone does not automatically mean that the treatment is appropriate.

How does Lutetium-177 PSMA therapy work?

Lutetium-177 is a radioactive isotope that emits beta radiation.

The isotope is attached to a molecule that binds to PSMA.

After intravenous administration, the compound travels through the bloodstream and can bind to PSMA-expressing cancer cells. Radiation is then delivered over a relatively short distance to the targeted cells and their immediate surroundings.

This can damage cancer cells while limiting radiation exposure to much of the surrounding normal tissue.

However, “targeted” does not mean that healthy tissue receives no radiation.

The kidneys, salivary glands, urinary system and bone marrow may also receive radiation exposure. For this reason, patient selection and monitoring remain important.

Is Lutetium-177 PSMA experimental?

No.

The treatment has now been evaluated in large randomized clinical trials and has received regulatory approvals in several clinical settings.

The earlier VISION trial studied men with PSMA-positive metastatic castration-resistant prostate cancer who had already received androgen-receptor pathway therapy and taxane chemotherapy.

Later trials evaluated Lutetium-177 PSMA earlier in the treatment sequence.

In March 2025, the U.S. FDA expanded the indication for Lutetium Lu-177 vipivotide tetraxetan to include selected patients with PSMA-positive metastatic castration-resistant prostate cancer who had already received an androgen receptor pathway inhibitor and for whom delaying taxane chemotherapy was considered appropriate.

The role of the therapy continued to move earlier.

In July 2026, the FDA approved Lutetium Lu-177 vipivotide tetraxetan in combination with androgen receptor pathway inhibitor therapy for selected patients with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.

This evolution is important.

Lutetium-177 PSMA should no longer be understood simply as a treatment used only after every other option has failed.

Its potential place in treatment now depends on the patient's exact clinical setting.

Who may be considered for treatment?

Eligibility is individualized.

A prostate-cancer team may consider factors including:

• disease stage;
• whether the cancer is metastatic;
• PSMA expression on approved PET imaging;
• previous hormone therapy;
• previous androgen receptor pathway inhibitors;
• previous chemotherapy;
• whether chemotherapy can appropriately be delayed;
• kidney function;
• blood counts and bone-marrow reserve;
• general medical condition;
• disease progression;
• alternative available treatments.

Regulatory indications and institutional criteria may differ between countries.

Eligibility should therefore be determined by qualified physicians reviewing the complete clinical case.

What does the evidence show?

The evidence depends on the patient population being discussed.

VISION

The phase III VISION trial involved 831 patients with PSMA-positive metastatic castration-resistant prostate cancer who had already received androgen receptor pathway therapy and one or two taxane regimens.

In that specific population:

• median overall survival was 15.3 months with Lutetium-177 PSMA plus standard care compared with 11.3 months with standard care alone;
• median imaging-based progression-free survival was 8.7 months compared with 3.4 months.

These results demonstrated a meaningful treatment benefit in the population studied.

They should not be interpreted as predicting how long any individual patient will live.

PSMAfore

The PSMAfore trial examined Lutetium-177 PSMA earlier, in patients with metastatic castration-resistant prostate cancer who had progressed after an androgen receptor pathway inhibitor but had not yet received taxane chemotherapy.

Radiographic progression-free survival was longer in the Lutetium-177 group than in the comparator group.

This evidence supported expansion of the treatment indication.

PSMAddition

More recently, the PSMAddition trial evaluated Lutetium-177 PSMA together with androgen receptor pathway inhibitor therapy in PSMA-positive metastatic androgen-sensitive disease.

The trial demonstrated a statistically significant improvement in radiographic progression-free survival.

This evidence contributed to expansion of the therapy into an earlier disease setting.

How is the treatment given?

Lutetium-177 PSMA therapy is administered intravenously.

For one widely approved Lutetium Lu-177 PSMA regimen, treatment is administered approximately every six weeks for up to six doses, or until disease progression or unacceptable toxicity.

The exact treatment pathway may vary depending on:

• the clinical indication;
• patient response;
• toxicity;
• local regulatory approval;
• and the treating institution's protocol.

Patients also undergo laboratory monitoring and radiation-safety procedures as part of treatment.

What are the possible side effects?

Potential adverse effects include:

• fatigue;
• nausea;
• dry mouth;
• decreases in blood-cell counts;
• bone-marrow suppression;
• effects on kidney function.

Because Lutetium-177 is radioactive, radiation-safety precautions are also necessary.

Regulatory prescribing information also warns about risks including radiation exposure, myelosuppression, renal toxicity, reproductive risks and infertility.

The treating medical team must evaluate these risks against the potential benefit for each individual patient.

What does “success rate” mean?

There is no single scientifically meaningful “success rate” for Lutetium-177 PSMA.

Success could mean several different things:

• reduction in PSA;
• tumor shrinkage;
• delayed disease progression;
• symptom improvement;
• prolonged survival;
• maintaining disease control for a period of time.

These outcomes vary according to disease stage, previous treatment, PSMA expression and individual patient characteristics.

For that reason, a single percentage quoted as the “success rate” can be misleading.

How much longer can Lutetium-177 extend life?

This question also requires context.

In the VISION trial population, median overall survival was 15.3 months with Lutetium-177 PSMA plus standard care compared with 11.3 months with standard care alone.

That difference describes the median results of a defined clinical-trial population.

It does not mean that an individual patient can expect a specific extension of life.

Some patients may derive greater benefit, some less, and some may not respond.

Newer treatment settings also differ from the population studied in VISION, so those survival figures should not automatically be applied to every patient receiving Lutetium-177 PSMA today.

What about the cost of treatment?

The cost of Lutetium-177 PSMA therapy can differ substantially between countries and healthcare systems.

It may depend on factors such as:

• the specific treatment protocol;
• number of treatment cycles;
• required imaging;
• laboratory testing;
• nuclear-medicine services;
• specialist assessment;
• insurance coverage;
• and additional medical needs.

For this reason, general internet price estimates should not be treated as reliable quotations.

Patients considering treatment should obtain current, case-specific information after medical eligibility and the required treatment pathway have been established.

What should a patient prepare for specialist review?

A specialist reviewing an advanced prostate-cancer case may require:

• pathology reports;
• recent imaging;
• PSMA PET images and report, if already performed;
• treatment history;
• androgen-deprivation and ARPI history;
• chemotherapy history;
• PSA history;
• relevant laboratory results;
• current medications;
• information about symptoms and functional status.

Additional documents may be requested depending on the individual case.

Why can a second medical opinion be useful?

Prostate-cancer treatment sequencing has become increasingly complex.

A patient may now face questions such as:

• Should treatment remain hormone-based?
• Should chemotherapy be considered?
• Is the disease sufficiently PSMA-positive?
• Is Lutetium-177 appropriate now?
• Would it be more appropriate later?
• Are genomic or molecular findings relevant?
• Are other targeted treatments or clinical trials available?

These are clinical decisions that require specialist review.

For patients considering treatment outside their home country, obtaining a medical review before making travel arrangements can help clarify whether international treatment should be explored and what additional information may first be required.

Frequently Asked Questions

Is Lutetium-177 PSMA chemotherapy?

No. It is a targeted radioligand therapy that uses a radioactive isotope linked to a molecule that recognizes PSMA.

Do all prostate cancers express PSMA?

No. PSMA expression varies, which is why molecular imaging is important before treatment.

Is PSMA PET required?

Appropriate PSMA-positive imaging is an important part of patient selection for approved PSMA-targeted treatment.

How many treatments are usually given?

One approved regimen uses treatment approximately every six weeks for up to six doses, although the exact course depends on the indication, response and treating institution.

Can treatment be performed on an outpatient basis?

In many settings treatment may be administered without an overnight hospital admission, subject to institutional protocol, the patient's medical condition and local radiation-safety requirements.

Is Lutetium-177 only a last-line treatment?

No. Its approved role has expanded into earlier treatment settings for selected PSMA-positive patients.

Does a PSMA-positive scan guarantee that the treatment will work?

No.

PSMA positivity helps establish that the biological target is present. It does not guarantee an individual response.

The key message

Lutetium-177 PSMA represents an important development in precision prostate-cancer treatment.

Its role has expanded significantly, and the therapy is now being evaluated and used at different points in the advanced prostate-cancer pathway.

But the essential principle remains:

the right patient, the right target, the right disease setting and the right treatment sequence.

The first question should therefore not simply be:

“Where can I receive Lutetium-177?”

It should be:

“Based on my PSMA imaging, treatment history and current disease status, is Lutetium-177 PSMA an appropriate part of my treatment pathway?”

That is a question for qualified physicians reviewing the individual medical case.

Need more information?

RKM INTL assists international patients with medical coordination, specialist review and access to appropriate healthcare pathways in Israel.

Patients seeking further information about a complex oncology case or a second medical opinion may contact RKM INTL for coordination of the appropriate next step.

Sources & Further Reading

• U.S. Food and Drug Administration — regulatory information and indication updates for Lutetium Lu-177 vipivotide tetraxetan
• National Cancer Institute — prostate cancer treatment and PSMA-targeted radioligand therapy information
• Sartor et al. — VISION Phase III Trial, New England Journal of Medicine, 2021
• PSMAfore Phase III clinical-trial evidence
• PSMAddition Phase III clinical-trial evidence

About RKM INTL

RKM INTL coordinates access for international patients to medical specialists and healthcare institutions in Israel, including second medical opinions, complex-case assessment and treatment coordination.

RKM INTL is officially registered as a Medical Tourism Agent with the Israeli Ministry of Health, Registration No. 816979.

This article is intended for general informational purposes only and does not constitute medical advice, diagnosis or a treatment recommendation. Eligibility for Lutetium-177 PSMA therapy must be determined by qualified physicians following individual clinical assessment.